The effect of silymarin on liver enzymes and serum lipid profiles in Iranian patients with non-alcoholic fatty liver disease: A double-blind randomized controlled trial

• DOI: 10.18502/abi.v1i2.14105
• Publication Date: 2023-11-20T07:48:22Z
• Authors: Somayeh Chahkandi; Reza Dabiri; Majid Mirmohammad...; Nasrin Amiri-Dash...; Mehdi Koushki
• Keywords: Lipid Profile; Liver enzyme

Objectives: The aim of this study was to evaluate the effect silymarin on liver enzyme levels and serum lipid profiles in patients with Non-Alcoholic Fatty Liver Disease (NAFLD), most common chronic disease worldwide. Methods: This randomized double-blinded clinical trial included 80 NAFLD referred gastrointestinal clinic Kowsar Hospital Semnan. Forty these were supplemented 150 mg twice a day for two months, while other 40 received placebo. Both groups advised follow hypertriglyceridemia correction lifestyle modification. Evaluation enzymes both performed at baseline after months. Results: results showed that use significantly reduced ALT (U/L) (58.72± 32.16 vs 42.2 ± 20.2, p = 0.003) AST (36.62± 13.46 30.3 9.7, 0.036) compared placebo group. Additionally, statistically significant reducing triglycerides (mg/dL) (189.5 65.5 164.6 91.3, 0.026), total cholesterol (192.8 40.3 174.07± 34.5, 0.027), LDL-cholesterol (114.6±33.9 95.6± 26.5, 0.012) found, no statistical difference HDL-C (41.5 6.8 43.5± 9.2, 0.44). Conclusion: Silymarin, dose daily, some markers NAFLD, suggesting compound could be novel therapy NAFLD.